Date:
December 18, 2014
Source:
Thomas Jefferson University
Summary:
The cause of prostate cancer may be linked to
Parkinson’s disease through a common enzyme family called sirtuins. Finding an
enzyme that regulates this process could provide excellent new prevention
approaches for this common malignancy, researchers say. Sirtuin enzymes have
been implicated in neurodegeneration, obesity, heart disease, and cancer.
Prostate cancer affects more than 23,000 men
this year in the USA however the individual genes that initiate prostate cancer
formation are poorly understood. Finding an enzyme that regulates this process
could provide excellent new prevention approaches for this common malignancy.
Sirtuin enzymes have been implicated in neurodegeneration, obesity, heart
disease, and cancer. Research published online Thursday (Dec 18th) in The
American Journal of Pathology show the loss of one of sirtuin (SIRT1)
drives the formation of early prostate cancer (prostatic intraepithelial
neoplasia) in mouse models of the disease.
"Using genetic deletion we found that
SIRT1 normally restrains prostatic intraepithelial neoplasia in animals.
Therefore too little SIRT1 may be involved in the cellular processes that
starts human prostate cancer," said Dr. Richard Pestell, M.D., Ph.D., MBA,
executive Vice President of Thomas Jefferson University and Director of the
Sidney Kimmel Cancer Center. "As we had shown that gene therapy based re
expression of SIRT1 can block human prostate cancer tumor growth, and SIRT1 is
an enzyme which can be targeted, this may be an important new target for
prostate cancer prevention."
The researchers led by Dr. Pestell, created a
mouse model that lacked SIRT1 and noticed that these mice were more likely to
develop an early form of prostate cancer called prostatic intraepithelial
neoplasia (PIN).
Other researchers had shown that SIRT1 can
defend the cell against damage from free radicals. Pestell's group took the
work further by showing that in this prostate cancer model, free radicals built
up in cells lacking SIRT1. They showed that normally, SIRT1 proteins help
activate a mitochondrial protein called SOD2, in turn activating those proteins
to keep free-radical levels in check. When SIRT1 level are diminished, SOD2 is
no longer effective at removing free radicals, allowing a dangerous build up in
the cells, and leading to PIN.
"The next step," says first author
Gabriele DiSante, Ph.D., a postdoctoral fellow in the department of Cell
Biology at Jefferson, "is to determine if this is also important in the
development of human prostate cancer."
This work was supported in part by awards from
the National Institutes of Health R01CA70896, R01CA75503 and R01CA86072. Work
conducted at the Sidney Kimmel Cancer Center was supported by the NIH Cancer
Center Core grant P30CA56036. This project was partially supported by the China
Scholarship Council. This project is funded in part by the Pennsylvania
Department of Health grant. The Department specifically disclaims
responsibility for any analyses, interpretations or conclusions.
Story Source:
The above story is based on materials
provided by Thomas Jefferson
University. Note: Materials may be edited for content and
length.
Journal Reference:
1
Gabriele Di Sante, Timothy G.
Pestell, Mathew C. Casimiro, Sara Bisetto, Michael J. Powell, Michael P.
Lisanti, Carlos Cordon-Cardo, Mireia Castillo-Martin, Dennis M. Bonal,
Valentina Debattisti, Ke Chen, Liping Wang, Xiaohong He, Michael W. McBurney,
Richard G. Pestell. Loss of Sirt1 Promotes Prostatic Intraepithelial
Neoplasia, Reduces Mitophagy, and Delays Park2 Translocation to Mitochondria.
The American Journal of Pathology, 2015; 185 (1): 266 DOI: 10.1016/j.ajpath.2014.09.014
Cite This Page:
•
MLA
APA
Chicago
Thomas Jefferson University.
"How does prostate cancer form? Parkinson's Link?." ScienceDaily.
ScienceDaily, 18 December 2014.
<www.sciencedaily.com/releases/2014/12/141218080827.htm>.
No comments:
Post a Comment